Benitec to Collaborate with Stanford University on Pain Drug | GenomeWeb

Benitec Biopharma this week said that it is collaborating with Stanford University to test its expressed RNAi-based neuropathic pain treatment, called Nervarna, in vivo.

Nervarna is designed to inhibit protein kinase C gamma, which plays a role in various cellular signaling pathways. Benitec aims to initially develop the drug for use in terminally ill cancer patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.